Trial Outcomes & Findings for Identifying Ideal Reimbursement "Dose" to Reduce Clinical Trial-related Financial Toxicity (NCT NCT05871125)
NCT ID: NCT05871125
Last Updated: 2026-05-18
Results Overview
Number of patients who receive all reimbursements: 80% retention of patients Number of retained patients who patients who complete surveys: 75% of survey completion while enrolled
COMPLETED
NA
39 participants
2 years
2026-05-18
Participant Flow
Participant milestones
| Measure |
Intervention: $1,000 Per Month
Cohort 1: Patients receiving reimbursement of $1,000 per month over 4 months, for a total of $4,000 over the course of the intervention.
|
Intervention: $900 Per Month
Cohort 2: Patients receiving reimbursement of $900 per month over 4 months, for a total of $3,600 over the course of the intervention.
|
|---|---|---|
|
Overall Study
STARTED
|
39
|
0
|
|
Overall Study
COMPLETED
|
33
|
0
|
|
Overall Study
NOT COMPLETED
|
6
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Identifying Ideal Reimbursement "Dose" to Reduce Clinical Trial-related Financial Toxicity
Baseline characteristics by cohort
| Measure |
Intervention: Patients Receiving $1,000 Per Month
n=33 Participants
Receiving reimbursement of $1,000 per month over the course of 4 months, for a total of $4,000 for the intervention.
|
Intervention: Patients Receiving $900 Per Month.
Receiving reimbursement of $900 per month over the course of 4 months, for a total of $3,600 for the intervention.
|
Total
n=33 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
52 years
n=11 Participants
|
—
|
52 years
n=20 Participants
|
|
Sex: Female, Male
Female
|
33 Participants
n=11 Participants
|
—
|
33 Participants
n=20 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=11 Participants
|
—
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=11 Participants
|
—
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=11 Participants
|
—
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=11 Participants
|
—
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Black or African American
|
16 Participants
n=11 Participants
|
—
|
16 Participants
n=20 Participants
|
|
Race (NIH/OMB)
White
|
17 Participants
n=11 Participants
|
—
|
17 Participants
n=20 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=11 Participants
|
—
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=11 Participants
|
—
|
0 Participants
n=20 Participants
|
PRIMARY outcome
Timeframe: 2 yearsPopulation: No cohort met the de-escalation criteria so all cohorts received a $1,000 per month reimbursement.
Number of patients who receive all reimbursements: 80% retention of patients Number of retained patients who patients who complete surveys: 75% of survey completion while enrolled
Outcome measures
| Measure |
Intervention: Reimbursement of $1,000 Per Month
n=39 Participants
Receiving reimbursement of $1,000 per month over 4 months, for a total of $4,000 over the course of the intervention
|
Intervention: Reimbursement of $900 Per Month
Receiving reimbursement of $900 per month over 4 months, for a total of $3,600 over the course of the intervention
|
|---|---|---|
|
Number of Patients Who Receive All Reimbursements and Who Complete Follow-up Surveys (Overall Feasibility of Intervention)
|
33 Participants
|
0 Participants
|
Adverse Events
Intervention: Reimbursement of $1,000 Per Month
Intervention: Reimbursement of $900 Per Month
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place